|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 471/04 | |
| A61K 31/437 | |||
| A61K 31/444 | |||
| A61P 35/00 |
| (11) | Patento numeris | 3461823 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17812632.2 |
| Europos patento paraiškos padavimo data | 2017-06-09 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-04-03 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-06-03 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/CN2017/087711 |
| Data | 2017-06-09 |
| (87) | Numeris | WO 2017/215521 |
| Data | 2017-12-21 |
| (30) | Numeris | Data | Šalis |
| 201610430773 | 2016-06-17 | CN |
| (72) |
CHEN, Minhua, CN
ZHANG, Yanfeng, CN
ZOU, Po, CN
ZHANG, Xiaoyu, CN
|
| (73) |
Crystal Pharmaceutical (Suzhou) Co., Ltd.,
B4-301 Biobay 218 Xinghu Street Suzhou Industrial Park, Suzhou, Jiangsu 215123,
CN
|
| (54) | PEXIDARTINIB HYDROCHLORIDE CRYSTAL FORMS, PREPARATION METHOD THEREFOR AND USE THEREOF |
| PEXIDARTINIB HYDROCHLORIDE CRYSTAL FORMS, PREPARATION METHOD THEREFOR AND USE THEREOF |